PortalPublikationenPresurgical treatment with sunitinib for renal cell carcinom...

Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus

Standard

Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. / Horn, T.; Thalgott, M. K.; Maurer, T.; Hauner, K.; Schulz, S.; Fingerle, A.; Retz, M.; Gschwend, J. E.; Kubler, H. R.

in: ANTICANCER RES, Jahrgang 32, Nr. 5, 05.2012, S. 1729-1735.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Horn, T, Thalgott, MK, Maurer, T, Hauner, K, Schulz, S, Fingerle, A, Retz, M, Gschwend, JE & Kubler, HR 2012, 'Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus', ANTICANCER RES, Jg. 32, Nr. 5, S. 1729-1735.

APA

Horn, T., Thalgott, M. K., Maurer, T., Hauner, K., Schulz, S., Fingerle, A., Retz, M., Gschwend, J. E., & Kubler, H. R. (2012). Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. ANTICANCER RES, 32(5), 1729-1735.

Vancouver

Horn T, Thalgott MK, Maurer T, Hauner K, Schulz S, Fingerle A et al. Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. ANTICANCER RES. 2012 Mai;32(5):1729-1735.

Bibtex

@article{35cd4b987a9f4b7db8613e82ec2a4e17,
title = "Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus",
abstract = "AIM: The feasibility and safety of a presurgical treatment approach with sunitinib for renal cell carcinoma (RCC) with level III/IV tumour thrombus in the inferior vena cava (IVC) were to be evaluated and its potential ability to reduce the surgical morbidity explored.PATIENTS AND METHODS: In our institution, we treated five consecutive patients with suspected RCC and a level III/IV IVC tumour thrombus with preoperative sunitinib (50 mg, 4 weeks on, 2 weeks off). Side dose effects were assessed and the effect on the tumour size and the dependent surgical approach documented with a computed tomographic scan before and after the treatment. The data were analyzed retrospectively.RESULTS: The overall tolerability to presurgical sunitinib was good. All procedures were carried out without perioperative complications. In four patients, a reduction in tumour size was observed, which resulted in avoidance of a bicavital surgical approach with cardiopulmonary bypass in one patient. This patient was diagnosed with papillary renal cancer; the other four patients had clear cell carcinomas.CONCLUSION: Presurgical treatment with sunitinib is able to ease surgery for RCC tumour thrombi regardless of the histological subtype in selected patients. In our series, surgery was possible without additional morbidity. Two courses of a presurgical therapy with sunitinib seems to be an appropriate duration. In accordance with previously published data, presurgical sunitinib treatment may become more widely used in RCC with level III/IV IVC tumour thrombi but administered with restraint in cases of level I/II thrombi. The effects on the risk of recurrence and survival remain to be evaluated prospectively.",
keywords = "Angiogenesis Inhibitors, Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Neoplastic Cells, Circulating, Pyrroles, Sunitinib, Vena Cava, Inferior, Venous Thrombosis, Journal Article",
author = "T. Horn and Thalgott, {M. K.} and T. Maurer and K. Hauner and S. Schulz and A. Fingerle and M. Retz and Gschwend, {J. E.} and Kubler, {H. R.}",
note = "1791-7530 Horn, Thomas Thalgott, Mark K Maurer, Tobias Hauner, Katharina Schulz, Stephan Fingerle, Alexander Retz, Margitta Gschwend, Jurgen E Kubler, Hubert R Journal Article Greece Anticancer Res. 2012 May;32(5):1729-35.",
year = "2012",
month = may,
language = "English",
volume = "32",
pages = "1729--1735",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

RIS

TY - JOUR

T1 - Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus

AU - Horn, T.

AU - Thalgott, M. K.

AU - Maurer, T.

AU - Hauner, K.

AU - Schulz, S.

AU - Fingerle, A.

AU - Retz, M.

AU - Gschwend, J. E.

AU - Kubler, H. R.

N1 - 1791-7530 Horn, Thomas Thalgott, Mark K Maurer, Tobias Hauner, Katharina Schulz, Stephan Fingerle, Alexander Retz, Margitta Gschwend, Jurgen E Kubler, Hubert R Journal Article Greece Anticancer Res. 2012 May;32(5):1729-35.

PY - 2012/5

Y1 - 2012/5

N2 - AIM: The feasibility and safety of a presurgical treatment approach with sunitinib for renal cell carcinoma (RCC) with level III/IV tumour thrombus in the inferior vena cava (IVC) were to be evaluated and its potential ability to reduce the surgical morbidity explored.PATIENTS AND METHODS: In our institution, we treated five consecutive patients with suspected RCC and a level III/IV IVC tumour thrombus with preoperative sunitinib (50 mg, 4 weeks on, 2 weeks off). Side dose effects were assessed and the effect on the tumour size and the dependent surgical approach documented with a computed tomographic scan before and after the treatment. The data were analyzed retrospectively.RESULTS: The overall tolerability to presurgical sunitinib was good. All procedures were carried out without perioperative complications. In four patients, a reduction in tumour size was observed, which resulted in avoidance of a bicavital surgical approach with cardiopulmonary bypass in one patient. This patient was diagnosed with papillary renal cancer; the other four patients had clear cell carcinomas.CONCLUSION: Presurgical treatment with sunitinib is able to ease surgery for RCC tumour thrombi regardless of the histological subtype in selected patients. In our series, surgery was possible without additional morbidity. Two courses of a presurgical therapy with sunitinib seems to be an appropriate duration. In accordance with previously published data, presurgical sunitinib treatment may become more widely used in RCC with level III/IV IVC tumour thrombi but administered with restraint in cases of level I/II thrombi. The effects on the risk of recurrence and survival remain to be evaluated prospectively.

AB - AIM: The feasibility and safety of a presurgical treatment approach with sunitinib for renal cell carcinoma (RCC) with level III/IV tumour thrombus in the inferior vena cava (IVC) were to be evaluated and its potential ability to reduce the surgical morbidity explored.PATIENTS AND METHODS: In our institution, we treated five consecutive patients with suspected RCC and a level III/IV IVC tumour thrombus with preoperative sunitinib (50 mg, 4 weeks on, 2 weeks off). Side dose effects were assessed and the effect on the tumour size and the dependent surgical approach documented with a computed tomographic scan before and after the treatment. The data were analyzed retrospectively.RESULTS: The overall tolerability to presurgical sunitinib was good. All procedures were carried out without perioperative complications. In four patients, a reduction in tumour size was observed, which resulted in avoidance of a bicavital surgical approach with cardiopulmonary bypass in one patient. This patient was diagnosed with papillary renal cancer; the other four patients had clear cell carcinomas.CONCLUSION: Presurgical treatment with sunitinib is able to ease surgery for RCC tumour thrombi regardless of the histological subtype in selected patients. In our series, surgery was possible without additional morbidity. Two courses of a presurgical therapy with sunitinib seems to be an appropriate duration. In accordance with previously published data, presurgical sunitinib treatment may become more widely used in RCC with level III/IV IVC tumour thrombi but administered with restraint in cases of level I/II thrombi. The effects on the risk of recurrence and survival remain to be evaluated prospectively.

KW - Angiogenesis Inhibitors

KW - Antineoplastic Agents

KW - Carcinoma, Renal Cell

KW - Humans

KW - Indoles

KW - Kidney Neoplasms

KW - Neoplastic Cells, Circulating

KW - Pyrroles

KW - Sunitinib

KW - Vena Cava, Inferior

KW - Venous Thrombosis

KW - Journal Article

M3 - SCORING: Journal article

C2 - 22593453

VL - 32

SP - 1729

EP - 1735

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 5

ER -